Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.
Actinogen Medical’s lead drug candidate, Xanamem®, has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases.
Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.
In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company is conducting a range of quality Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.
ACW Anti-Bribery and Corruption Policy
ACW Audit Committee Charter
ACW Board Charter
ACW Code of Conduct
ACW Continuous Disclosure Policy
ACW Directors’ Skills Matrix
ACW Diversity Policy
ACW Nomination Committee Charter
ACW Performance Evaluation Practices
ACW Procedures for Selection and Appointment of Directors
ACW Remuneration Committee Charter
ACW Remuneration Policy
ACW Risk Management and Internal Compliance and Control
ACW Securities Trading Policy
ACW Shareholders Communication Policy
ACW Whistleblower Policy